Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Buy” by Brokerages

Immuneering Corporation (NASDAQ:IMRX) has received an average rating of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.50.

Several analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on Immuneering in a research note on Wednesday, July 8th. They set an “overweight” rating and a $17.00 target price on the stock. UBS Group set a $14.00 price target on Immuneering in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Chardan Capital raised Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. Finally, Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st.

Immuneering Trading Down 1.5%

Shares of NASDAQ:IMRX opened at $5.15 on Thursday. The firm’s 50 day moving average is $4.79 and its two-hundred day moving average is $5.00. The firm has a market capitalization of $333.20 million, a P/E ratio of -4.95 and a beta of 0.43. Immuneering has a 52 week low of $3.86 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Analysts predict that Immuneering will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Immuneering during the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Immuneering in the fourth quarter worth $33,000. Levin Capital Strategies L.P. acquired a new position in shares of Immuneering during the 1st quarter valued at about $53,000. Focus Financial Network Inc. acquired a new position in Immuneering during the second quarter valued at approximately $62,000. Finally, Cetera Investment Advisers acquired a new position in Immuneering during the first quarter valued at approximately $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.